Why use Retrogenix?
Ensuring that a novel biotherapeutic is specific to its intended target is undoubtedly advantageous when selecting promising lead candidates, however, it becomes vital when assessing potential safety implications prior to clinical studies.
Retrogenix specificity screening data has been readily accepted in applications for clinical trials and marketing approval in the US, Europe, China & Japan. Further details can be found in our case study using the link below. Or, to find out more, please get in touch with a member of our team.